Dr. Reddy’s Tosymra (sumatriptan nasal spray) 10mg Receives the US FDA Approval for Acute Treatment of Migraine

 Dr. Reddy’s Tosymra (sumatriptan nasal spray) 10mg Receives the US FDA Approval for Acute Treatment of Migraine

Dr. Reddy’s Tosymra (sumatriptan nasal spray) 10mg Receives the US FDA Approval for Acute Treatment of Migraine

Shots:

  • The approval is based on the clinical trial assessing Tosymra in patients with a migraine and demonstrated well tolerated and safe results
  • Promius Pharma’s (subsidiary of Dr. Reddy) Tosymra (previously known as DFN-02) is a nasal spray developed using Intravail platform, targeted to treat adults with migraine with or without aura, to achieve equivalent blood level developed with the usage of 4-mg sumatriptan SC injection
  • Intravail is a non-invasive drug delivery technology enabling delivery of multiple proteins, peptides and non-peptide drugs offering oral and buccal including dermal, and intranasal routes of drug administration

Click here  to read full press release/ article | Ref: Dr. Reddy | Image: Twitter

 

 

 

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post